SiBone (NASDAQ:SIBN) SVP Sells $394,940.00 in Stock

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 19,600 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $20.15, for a total transaction of $394,940.00. Following the sale, the senior vice president directly owned 231,896 shares in the company, valued at approximately $4,672,704.40. The trade was a 7.79% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

SiBone Trading Up 0.6%

NASDAQ SIBN opened at $20.38 on Monday. The firm’s fifty day moving average price is $17.42 and its 200 day moving average price is $16.85. SiBone has a 12 month low of $12.49 and a 12 month high of $20.80. The company has a debt-to-equity ratio of 0.21, a current ratio of 7.97 and a quick ratio of 6.62. The company has a market capitalization of $884.31 million, a price-to-earnings ratio of -39.96 and a beta of 0.76.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. The firm had revenue of $48.66 million during the quarter, compared to analysts’ expectations of $46.67 million. SiBone had a negative net margin of 11.24% and a negative return on equity of 12.86%. On average, sell-side analysts expect that SiBone will post -0.78 earnings per share for the current fiscal year.

Key Headlines Impacting SiBone

Here are the key news stories impacting SiBone this week:

• Positive Sentiment: Canaccord raised its price target on SIBN from $26 to $27 and maintained a Buy rating, signaling stronger upside expectations that support further upside for the shares. Read More.
• Positive Sentiment: Truist increased its price target from $21 to $23 and kept a Buy rating, adding incremental broker support for the stock’s near-term rally. Read More.
• Positive Sentiment: Needham published a bullish forecast calling for strong price appreciation for SIBN, adding another institutional voice to the buy-side narrative. Read More.
• Positive Sentiment: Market headlines reported SIBN trading up roughly 5.4% after analyst upgrades, reflecting immediate market reaction to the research updates and lifting momentum. Read More.
• Negative Sentiment: CFO Anshul Maheshwari sold 18,542 shares at an average price of $20.15 (total ~$373,621); the filing shows his holding decreased about 9.1%. Insider selling can raise short-term concern about insider conviction, even if sales are for personal reasons. Read More.
• Negative Sentiment: SVP Michael A. Pisetsky sold 19,600 shares at an average of $20.15 (total ~$394,940); his position fell ~7.8% after the trade. Multiple insider disposals the same day can amplify investor caution. Read More.

Institutional Trading of SiBone

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in SiBone by 1.5% during the first quarter. Vanguard Group Inc. now owns 2,444,159 shares of the company’s stock worth $34,292,000 after purchasing an additional 35,349 shares in the last quarter. Invesco Ltd. increased its position in SiBone by 82.8% during the 1st quarter. Invesco Ltd. now owns 31,448 shares of the company’s stock worth $441,000 after purchasing an additional 14,245 shares during the period. Russell Investments Group Ltd. raised its stake in shares of SiBone by 765.3% during the 1st quarter. Russell Investments Group Ltd. now owns 201,758 shares of the company’s stock worth $2,831,000 after buying an additional 178,442 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of SiBone by 11.1% in the 1st quarter. American Century Companies Inc. now owns 2,642,322 shares of the company’s stock valued at $37,072,000 after buying an additional 264,254 shares during the period. Finally, Quantbot Technologies LP purchased a new stake in shares of SiBone in the first quarter valued at approximately $158,000. Hedge funds and other institutional investors own 98.11% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on SIBN. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SiBone in a research report on Monday, December 15th. Truist Financial raised their target price on shares of SiBone from $21.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday. Morgan Stanley upped their price target on shares of SiBone from $20.00 to $23.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. Canaccord Genuity Group increased their price target on shares of SiBone from $26.00 to $27.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Needham & Company LLC lifted their price objective on shares of SiBone from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $25.00.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.